Belite Bio (BLTE) logo

Belite Bio (BLTE) stock

Retinal medicines , market cap $6.1B

$127.38
-15.65%

Why is BLTE down?

Down 25% from Nov 12 to Nov 20 while the S&P 500 fell 9%.

“Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant.”

Belite Bio fell 25% from Nov 12 to Nov 20. It fell 16% on Nov 20 alone. Its release on Nov 20 said

Sources: Price history, Nov 20, 2026; Company release (8-K), Nov 20, 2026

−1Profit A loss of $77.6M in the year to Dec 31, 2025, more than the $36.1M lost the year before, from the SEC filing

Tell me next time BLTE moves

Free account, no card. An optional alert when BLTE moves or its score changes.Pro, $1 for a first month. An optional alert when BLTE moves or its score changes.Pro, 7 days free with a card. An optional alert when BLTE moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on BLTE →2 more reasons why BLTE fell 25% since Nov 12, from its filings, with the other side, the timeline, and its peers, for Pro members.

Why BLTE still beats the market over three years

Up 233% over the three years to Nov 20 while the S&P 500 rose 58%; down 25% since Nov 12.

3 reasons, from its filings, with the timeline and its peers, for Pro members.

Quality Score
-1
Poor
In its industry
#122of 273
Checks firing
1of 14
Transition
From 52-week high
-36.3%
under its best in a year

BLTE's Quality Score rose 1 point on Fri, Nov 20, to -1. More shares traded than usual.

Follow BLTE's trial news. Pro members can get an alert when Belite Bio files news, and see its trials, share raises, and its CEO's filings.

Get an alert when BLTE files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextMay 12, 2027 · In 172 days“with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027…”FDA decision date · SEC filing · Nov 20Moved from Feb 12, 2027

Key facts on BLTE

Key facts on BLTE
Holding it backA $78M loss wider than $36M a year earlier
Latest filing6-K, Nov 20 Issued a release: "Belite Bio Announces Extension of FDA Review Timeline for Tinlarebant"

BLTE in the news

YesterdayBelite Bio Announces Extension of FDA Review Timeline for Tinlarebant NDA Business Insider and 10 more

Outlet counts from the GDELT Project.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

BLTE catalysts

Coming up

After its last 4 reports it closed -0.5% on average, higher 2 of 4 times.

4 past catalysts since 2026, with sizes and sources, for Pro members.

What's next for BLTE, and how long its cash lasts

Next step the company has named

May 12, 2027In 172 days“with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027, and (ii) if no major deficiencies are identified”FDA decision date · SEC filing · Nov 20

What it means: the date by which the FDA has said it aims to decide on the company’s application. The FDA can decide earlier, or extend the date.

A trial underway
PHOENIXPhase 3 · Active · 429 people · main data estimated Jun 30, 2027 · NCT05949593

1 more trial, 39 filings, for Pro members.

Cash runway Dec 31, 2025 balance sheet

$492M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. It has raised money since that balance sheet, which is not counted here.

For Pro members: whether the cash lasts past the FDA date, the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 5 raises and their amounts, and the share count against a year ago.

Insiders

Chief Medical Officer Hendrik Peter Scholl sold 2,000 shares on Nov 12, under a planned sale. 27 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Yu-Hsin Lin’s 7 filings and quotes.

Get an alert before BLTE's FDA date

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How BLTE ranks in Biotech

BLTE is #122 of 273 by Quality Score.

How BLTE ranks in Biotech
RankStockQuality Score
122Belite Bio (BLTE) logoBLTEBelite Bio-1

More in Biotech

When does BLTE report earnings, and what happens after?

Expected to report Mon Mar 1, before the open (in 100 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

Close after the report, last 3

+2.6%-7.1%+9.0%
May 20Aug 13Nov 12
ReportedGapReaction5
days
Nov 12, 2026Before open+0.9%+9.0%+0.2%
Aug 13, 2026Before open0.0%-7.1%-5.8%
May 20, 2026Before open+1.7%+2.6%+1.7%

BLTE closed higher after 2 of its last 4 reports.

All 4 reports, and BLTE's Quality Score going into each

BLTE has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on BLTE, and all 14 on every stock.Get in free →See the top 3 →Start Pro

BLTE RSI on Nov 20: 31.6, below its 50-day and 200-day averages

Not scored

RSI 31.6, MACD below signal, below both averages. Not scored.

3 more findings on BLTE, each with its source, for Pro members.

BLTE share count over time

Shares: 9.8% more than a year ago (to Dec 31).

Shares of BLTE outstanding, as filed
Shares
outstanding
As
of
39.3MDec 31, 2025
31.8MDec 31, 2024
29.1MDec 31, 2023
24.9MDec 31, 2022
Offerings, shelves, and splits of BLTE, from its filings
From its
filings
Filed
Priced a sale of sharesNov 17, 2026
Priced a sale of sharesDec 2, 2025
Registered shares for a later sale (F-3ASR)Oct 22, 2025
Priced a sale of sharesAug 8, 2025

3 more offerings on file, for Pro members.

BLTE insider trades

One insider sold $2.9M across 13 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellHendrik Peter Scholl$707KChief Medical Officerat $145.43 on Jun 18, filed Jun 22

All 13 insider filings on BLTE from the last six months, for Pro members.

All BLTE insider trades

BLTE's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

About Belite Bio

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

41 employeesbelitebio.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on BLTE and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn BLTE's score around: 7 things
  • 10 more filings explained, a plain line each
  • 2 more things pulling BLTE's score down
BreakawayJun 22Hendrik Peter Scholl sold BLTE$707K at $145.43, filed Jun 22

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: BLTE's Quality Score is -1 (Poor), #122 of 273 in Biotech. Insiders sold $2.9M in the last 6 months (Form 4).

What does BLTE's Quality Score say?

BLTE scores -1 today, which Breakaway calls Poor. It is #122 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 25% from Nov 12 to Nov 20 while the S&P 500 fell 9%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is BLTE's Quality Score?

BLTE scores -1 today, which Breakaway calls Poor (below zero). That is #122 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BLTE's -1.

Are insiders buying BLTE?

One insider sold $2.9M across 13 filings in the last 6 months. No open-⁠market buys on record. The newest is Hendrik Peter Scholl, Chief Medical Officer, who sold $707K on Jun 18. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Belite Bio: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.